Go Pro
→ How options let you do more with less capital (From Base Camp Trading) (Ad)tc pixel Free SMFL Stock Alerts

Smart for Life (SMFL) Competitors

Smart for Life logo
Compare

SMFL vs. EFTR, CMRA, STAB, EVLO, and SXTPW

Should you buy Smart for Life stock or one of its competitors? Smart for Life's main competitors and comparable companies include eFFECTOR Therapeutics (EFTR), Comera Life Sciences (CMRA), Statera Biopharma (STAB), Evelo Biosciences (EVLO), and 60 Degrees Pharmaceuticals (SXTPW). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Smart for Life compare to eFFECTOR Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Smart for Life has higher revenue and earnings than eFFECTOR Therapeutics. eFFECTOR Therapeutics is trading at a lower price-to-earnings ratio than Smart for Life, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$13.08N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Smart for Life N/A N/A N/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Smart for Life Neutral

eFFECTOR Therapeutics has a beta of 2.48, indicating that its share price is 148% more volatile than the broader market. Comparatively, Smart for Life has a beta of 17.51, indicating that its share price is 1,651% more volatile than the broader market.

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. Comparatively, 28.4% of Smart for Life shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by insiders. Comparatively, 31.7% of Smart for Life shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Smart for Life beats eFFECTOR Therapeutics on 5 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Comera Life Sciences has a beta of 1.05, indicating that its share price is 5% more volatile than the broader market. Comparatively, Smart for Life has a beta of 17.51, indicating that its share price is 1,651% more volatile than the broader market.

28.4% of Smart for Life shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 31.7% of Smart for Life shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Smart for Life Neutral

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Smart for Life N/A N/A N/A

Comera Life Sciences has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Summary

Smart for Life beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Smart for Life compare to Statera Biopharma?

Statera Biopharma (NASDAQ:STAB) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Statera Biopharma has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Smart for Life has a beta of 17.51, suggesting that its share price is 1,651% more volatile than the broader market.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Smart for Life Neutral

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Smart for Life N/A N/A N/A

Statera Biopharma has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

28.4% of Smart for Life shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by company insiders. Comparatively, 31.7% of Smart for Life shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Smart for Life beats Statera Biopharma on 5 of the 5 factors compared between the two stocks.

How does Smart for Life compare to Evelo Biosciences?

Evelo Biosciences (NASDAQ:EVLO) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

Evelo Biosciences has a beta of 1.62, suggesting that its stock price is 62% more volatile than the broader market. Comparatively, Smart for Life has a beta of 17.51, suggesting that its stock price is 1,651% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Evelo BiosciencesN/A N/A N/A
Smart for Life N/A N/A N/A

Smart for Life has higher revenue and earnings than Evelo Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Evelo BiosciencesN/AN/A-$114.53M-$4.21N/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

0.3% of Evelo Biosciences shares are owned by institutional investors. Comparatively, 28.4% of Smart for Life shares are owned by institutional investors. 1.0% of Evelo Biosciences shares are owned by company insiders. Comparatively, 31.7% of Smart for Life shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Evelo Biosciences' average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Evelo Biosciences Neutral
Smart for Life Neutral

Summary

Smart for Life beats Evelo Biosciences on 6 of the 7 factors compared between the two stocks.

How does Smart for Life compare to 60 Degrees Pharmaceuticals?

Smart for Life (NASDAQ:SMFL) and 60 Degrees Pharmaceuticals (NASDAQ:SXTPW) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Company Net Margins Return on Equity Return on Assets
Smart for LifeN/A N/A N/A
60 Degrees Pharmaceuticals N/A N/A N/A

60 Degrees Pharmaceuticals has lower revenue, but higher earnings than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Smart for Life$11.11M0.00-$22.68M-$14.48N/A
60 Degrees Pharmaceuticals$1.11MN/AN/AN/AN/A

In the previous week, 60 Degrees Pharmaceuticals had 1 more articles in the media than Smart for Life. MarketBeat recorded 1 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Smart for Life. 60 Degrees Pharmaceuticals' average media sentiment score of 0.30 beat Smart for Life's score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Smart for Life Neutral
60 Degrees Pharmaceuticals Neutral

28.4% of Smart for Life shares are owned by institutional investors. 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Smart for Life beats 60 Degrees Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

Get Smart for Life News Delivered to You Automatically

Sign up to receive the latest news and ratings for SMFL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SMFL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

SMFL vs. The Competition

Export
MetricSmart for LifePharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.41B$7.20B$14.00B
Dividend YieldN/A2.64%2.57%12.64%
P/E Ratio0.00797.31274.0725.48
Price / SalesN/A791.08676.41100.02
Price / CashN/A87.3377.0151.20
Price / BookN/A10.5210.476.27
Net Income-$22.68M$2.81B$3.48B$358.12M

Smart for Life Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SMFL
Smart for Life
N/AN/AN/AN/A$1K$11.11MN/A110
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/A+0.0%$4KN/AN/A10
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
STAB
Statera Biopharma
N/A$0.00
flat		N/A+100.0%$3KN/AN/A20
EVLO
Evelo Biosciences
N/AN/AN/AN/A$2KN/AN/A120

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SMFL) was last updated on 9/18/2026 by MarketBeat.com Staff.
From Our Partners
A “bloodbath” Is Coming
Reports suggest some Silicon Valley billionaires are stockpiling gold, guns, and gas masks - or leaving the co...
TradeSmith | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
The national debt just passed $39 trillion
The U.S. national debt just topped $39 trillion, up nearly $3 trillion in a single year and on pace to hit $40...
US Gold Bureau | Sponsoredtc pixel
This Gold Explorer Is Approaching Its Biggest Milestone Yet
A little-known Arizona gold explorer just hit 66.2 metres grading 6.57 g/t gold, including 20.7 metres at 18.2...
Wall Street Logic | Sponsoredtc pixel
Why major institutions are piling into this digital asset now
BlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...
Awesomely | Sponsoredtc pixel
How options let you do more with less capital
Would you rather spend $5,000 buying 100 shares of a $50 stock, or control those same 100 shares for a fractio...
Base Camp Trading | Sponsoredtc pixel
Iran War: Why Is Trump Protecting THEM?
A powerful Middle Eastern government is reportedly seeking US intelligence, targeting help, and military prote...
Banyan Hill Publishing | Sponsoredtc pixel